CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study

Martin Reck, Koichi Hagiwara, Baohui Han, Sergei Tjulandin, Christian Grohé, Takashi Yokoi, Alessandro Morabito, Silvia Novello, Edurne Arriola, Olivier Molinier, Rose McCormack, Marianne Ratcliffe, Nicola Normanno

Research output: Contribution to journalArticle

Abstract

Introduction: To offer patients with EGFR mutation- positive advanced NSCLC appropriate EGFR tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic samples are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for EGFR mutation testing. Methods: ASSESS was conducted in 56 centers (in Europe and Japan). Eligible patients (with newly diagnosed locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytologic and plasma samples. DNA extracted from tissue/cytologic samples was subjected to EGFR mutation testing using local practices; designated laboratories performed DNA extraction/mutation testing of blood samples. The primary end point was level of concordance of EGFR mutation status between matched tissue/cytologic and plasma samples. Results: Of 1311 patients enrolled, 1288 were eligible. Concordance ofmutation status in 1162matched sampleswas 89% (sensitivity 46%, specificity 97%, positive predictive value 78%, and negative predictive value 90%). A group of 25 patients with apparent false-positive plasma results was overrepresented for cytologic samples, use of less sensitive tissue testing methodologies, and smoking habits associated with high EGFR mutation frequency, indicative of falsenegative tumor results. In cases in which plasma and tumor samples were tested with identical highly sensitive methods, positive predictive value/sensitivitywere generally improved. Conclusions: These real-world data suggest that ctDNA is a feasible sample for EGFR mutation analysis. It is important to conduct mutation testing of both tumor and plasma samples in specialized laboratories, using robust/sensitive methods to ensure that patients receive appropriate treatments that target the molecular features of their disease.

Original languageEnglish
Pages (from-to)1682-1689
Number of pages8
JournalJournal of Thoracic Oncology
Volume11
Issue number10
DOIs
Publication statusPublished - 2016

Keywords

  • CtDNA
  • EGFR mutation
  • NSCLC
  • Plasma
  • Realworld

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study'. Together they form a unique fingerprint.

  • Cite this

    Reck, M., Hagiwara, K., Han, B., Tjulandin, S., Grohé, C., Yokoi, T., Morabito, A., Novello, S., Arriola, E., Molinier, O., McCormack, R., Ratcliffe, M., & Normanno, N. (2016). CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study. Journal of Thoracic Oncology, 11(10), 1682-1689. https://doi.org/10.1016/j.jtho.2016.05.036